Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/30/2026

1. SPY
2. AVAV
3. NVDA
4. MU
5. DLR
6. EOSE
7. NKE
8. AAPL
9. TSLA
10. VSH

Go back to Minerva Neurosciences Announces Results From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia
(NASDAQ: NERV) Delayed: 5.55 +0.12 (2.21%)
Previous Close $5.43    52 Week High $15.84 
Open $5.47    52 Week Low $3.45 
Day High $5.84    P/E N/A 
Day Low $5.41    EPS $0.00 
Volume 221,302